FDA to review supplemental Biologics License Application for Praluent alirocumab Injection as potential treatment to reduce major adverse cardiovascular events

FDA to review supplemental Biologics License Application for Praluent alirocumab Injection as potential treatment to reduce major adverse cardiovascular events FDA also recently approved Praluent label update for some patients currently requiring LD...